Alnylam Pharmaceuticals (ALNY) Earnings Date, Estimates & Call Transcripts

$241.53 +1.45 (+0.60%)

As of 12:36 PM Eastern

Alnylam Pharmaceuticals Earnings Summary

Alnylam Pharmaceuticals issued Q2 2026 earnings on July 30, 2026, reporting an EPS of $1.84, which beat analysts' consensus estimates of $1.63 by $0.21. Quarterly revenue rose 66.9% year-over-year to $1.29 billion, below the consensus estimate of $1.32 billion. With a trailing EPS of $5.38 and a P/E Ratio of 44.86, Alnylam Pharmaceuticals' earnings are expected to grow 46.43% next year, from $6.59 to $9.65 per share.

Upcoming Q3 Earnings Date: Oct. 29Before Market OpensEstimated
Consensus EPS (Jul. 30): $1.63
Actual EPS (Jul. 30): $1.84 Beat By $0.21
Actual Revenue (Jul. 30): $1.29B

Q2 2026 Earnings Resources

ALNY Upcoming Earnings

Alnylam Pharmaceuticals' next earnings date is estimated for Thursday, October 29, 2026, based on past reporting schedules.

Slide Deck

Full Screen Slide Deck

Get Alnylam Pharmaceuticals Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Alnylam Pharmaceuticals and other key companies, straight to your inbox.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ALNY Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

ALNY Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Alnylam Pharmaceuticals Analyst EPS Estimates

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2026	1	-$0.05	-$0.05	-$0.05
Q2 2026	2	-$0.15	$1.00	$0.43
Q3 2026	2	$0.07	$1.65	$0.86
Q4 2026	2	-$0.08	$1.97	$0.95

Alnylam Pharmaceuticals Earnings History by Quarter

Time Frame

Start Date

End Date

Export

Date	Quarter	Consensus Estimate	Reported EPS	Beat/Miss	GAAP EPS	Revenue Estimate	Actual Revenue	Details
10/29/2026 (Estimated)	-	-	-	-	-	-	-	-
7/30/2026	Q2 2026	$1.63	$1.84	+$0.21	$1.21	$1.32B	$1.29B
4/30/2026	Q1 2026	$0.8720	$1.99	+$1.1180	$1.51	$1.12B	$1.17B
2/12/2026	Q4 2025	$1.43	$1.25	-$0.18	$0.82	$1.16B	$1.10B
7/31/2025	Q2 2025	-$0.54	$0.32	+$0.86	-$0.51	$633.54M	$773.69M
5/1/2025	Q1 2025	-$0.37	-$0.44	-$0.07	-$0.44	$584.32M	$594.19M
2/13/2025	Q4 2024	-$0.62	-$0.65	-$0.03	-$0.65	$580.62M	$593.17M
10/31/2024	Q3 2024	-$0.51	-$0.87	-$0.36	-$0.87	$532.91M	$500.90M

Alnylam Pharmaceuticals Earnings - Frequently Asked Questions

Alnylam Pharmaceuticals has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, October 29th, 2026 based off last year's report dates. Learn more on ALNY's earnings history.

Alnylam Pharmaceuticals issued an update on its FY 2026 earnings guidance on Thursday, July, 30th. The company issued revenue guidance of $5.3 billion-$5.7 billion, compared to the consensus revenue estimate of $5.6 billion.

In the previous quarter, Alnylam Pharmaceuticals (NASDAQ:ALNY) reported $1.84 earnings per share (EPS) to beat the analysts' consensus estimate of $1.63 by $0.21. Learn more on analysts' earnings estimate vs. ALNY's actual earnings.

The conference call for Alnylam Pharmaceuticals' latest earnings report can be listened to online.
Listen to Conference Call

The conference call transcript for Alnylam Pharmaceuticals' latest earnings report can be read online.
Read Transcript

Alnylam Pharmaceuticals' earnings report can be found in their filing with the SEC.
View SEC filing

Alnylam Pharmaceuticals (NASDAQ:ALNY) has a recorded annual revenue of $4.80 billion.

Alnylam Pharmaceuticals (NASDAQ:ALNY) has a recorded net income of $313.75 million. ALNY has generated $5.38 earnings per share over the last four quarters.

Alnylam Pharmaceuticals (NASDAQ:ALNY) has a trailing price-to-earnings ratio of 44.92 and a forward price-to-earnings ratio of 36.61.

Alnylam Pharmaceuticals' earnings are expected to grow from $6.59 per share to $9.65 per share in the next year, which is a 46.43% increase.

More Earnings Resources from MarketBeat

Related Companies

Earnings Tools

Latest Articles

Earnings data for NASDAQ:ALNY is sourced from Fiscal.ai, with the most recent quarter reported on 7/30/2026. New results are added as companies report their earnings.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Alnylam Pharmaceuticals (ALNY) Earnings Date, Estimates & Call Transcripts